Progress and Challenges in Screening for Early Detection of Ovarian Cancer*
暂无分享,去创建一个
[1] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[2] R. Kryscio,et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. , 1997, Gynecologic oncology.
[3] B. Nilsson,et al. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. , 2002, Gynecologic oncology.
[4] T. Bourne,et al. Feasibility Study of a Randomised Trial of Ovarian Cancer Screening among the General Population , 1994, Journal of medical screening.
[5] A. Tabor,et al. Feasibility Study of a Randomised Trial of Ovarian Cancer Screening , 1994, Journal of medical screening.
[6] B. Mol,et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. , 2001, Gynecologic oncology.
[7] R. Berkowitz,et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. , 1993, Gynecologic oncology.
[8] R. Kryscio,et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. , 1998, Gynecologic oncology.
[9] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.
[10] I. Timor-Tritsch,et al. Transvaginal Sonographic Characterization of Ovarian Disease: Evaluation of a New Scoring System to Predict Ovarian Malignancy , 1991, Obstetrics and gynecology.
[11] L. Valentin,et al. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[12] E. Diamandis. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.
[13] J. Satagopan,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.
[14] Steven J Skates,et al. Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.
[15] O. Mogensen,et al. Neural networks in the diagnosis of malignant ovarian tumours , 1999, British journal of obstetrics and gynaecology.
[16] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.
[17] R. Bast,et al. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. , 1999, Clinical chemistry.
[18] I. Jansson,et al. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. , 1989, Gynecologic oncology.
[19] G. Yousef,et al. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. , 2000, Clinical biochemistry.
[20] Liam D. Turner,et al. Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.
[21] T. R. Holbert. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. , 1994, American journal of obstetrics and gynecology.
[22] E. Thomson,et al. Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .
[23] Rainer Cramer,et al. Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. , 2003, Clinical science.
[24] J. Grudzinskas,et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. , 1993, BMJ.
[25] R. Bast,et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. , 1999, Gynecologic oncology.
[26] R. Bast,et al. Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[27] R. Bast,et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. , 1993, Journal of the National Cancer Institute.
[28] R. Borovik,et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging , 1993, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[29] I. Timor-Tritsch,et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. , 1994, American journal of obstetrics and gynecology.
[30] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[31] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[32] P. Schwartz,et al. Early detection and screening for ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.
[33] S. Guerriero,et al. Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler? , 2002, Gynecologic oncology.
[34] A. Monteagudo,et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. , 1993, American journal of obstetrics and gynecology.
[35] H. Burger,et al. Inhibins/activins as diagnostic markers for ovarian cancer , 2002, Molecular and Cellular Endocrinology.
[36] E. Kohn,et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.
[37] R. Berkowitz,et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.
[38] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[39] V. Zurawski,et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer , 1988, International journal of cancer.
[40] K Offit,et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. , 1997, JAMA.
[41] R. Millo,et al. Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer? , 1990, Clinical and experimental obstetrics & gynecology.
[42] T. Bourne,et al. The potential role of serum CA 125 in an ultrasound‐based screening program for familial ovarian cancer , 1994, Gynecologic oncology.
[43] D. Pauler,et al. Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers , 2001 .
[44] E. Thomson,et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. , 1997, JAMA.
[45] M. Nap. Immunohistochemistry of CA 125 , 1998, The International journal of biological markers.
[46] B. Karlan,et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[47] B. Rockhill. Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.
[48] R. Berkowitz,et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.
[49] J. Seelen,et al. Transvaginal colour flow imaging and ovarian cancer. , 1990, BMJ.
[50] R. Bast,et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. , 1991, American journal of obstetrics and gynecology.
[51] R. Berkowitz,et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. , 1998, Journal of the National Cancer Institute.
[52] P. Kenemans,et al. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. , 1993, Clinical chemistry.
[53] R. L. Baldwin,et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. , 1999, American journal of obstetrics and gynecology.
[54] G. Adonakis,et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. , 1996, European journal of obstetrics, gynecology, and reproductive biology.
[55] P. Doubilet,et al. Ovarian Masses: Can Benign and Malignant Lesions be Differentiated with Color and Pulsed Doppler US? , 1994, Radiology.
[56] W P Collins,et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. , 1999, American journal of obstetrics and gynecology.
[57] R. Kryscio,et al. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. , 2003, Gynecologic oncology.
[58] J. Satagopan,et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Jakubowska,et al. [Hereditary ovarian cancer: summary of 5 years of experience]. , 1998, Ginekologia Polska.
[60] I. Jacobs,et al. PREVALENCE SCREENING FOR OVARIAN CANCER USING RISK OF OVARIAN CANCER ALGORITHM , 2003, International Journal of Gynecologic Cancer.
[61] E J Pavlik,et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. , 2000, Gynecologic oncology.
[62] Qing-Yu He,et al. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study , 2003, Proteomics.
[63] Gordon B Mills,et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. , 2003, Gynecologic oncology.
[64] K. Heimdal,et al. Prospectively detected cancer in familial breast/ovarian cancer screening , 1999, Acta obstetricia et gynecologica Scandinavica.
[65] R. Bast,et al. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15‐3 and TAG 72.3 , 1993, British journal of obstetrics and gynaecology.
[66] F. Kikkawa,et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. , 1996, Gynecologic oncology.
[67] Min Zhan,et al. A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.
[68] Weimin Zhu,et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. , 2003, Journal of proteome research.
[69] S. Ramakrishnan,et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. , 1991, Cancer research.
[70] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[71] Ja Wilson,et al. Principles and practice of screening for disease , 1968 .
[72] Steven J Skates,et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] P. Wilkinson,et al. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. , 1984, British Journal of Cancer.
[74] I. Jacobs,et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study , 1996, BMJ.
[75] G. Yousef,et al. Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers , 2002, Tumor Biology.
[76] Usha Menon,et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening , 2000, BJOG : an international journal of obstetrics and gynaecology.
[77] M Nap,et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[78] A. Kurjak,et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. , 1994, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[79] R. Bast,et al. CA 125 in ovarian cancer: advances and controversy. , 1998, Clinical chemistry.
[80] P. Møller,et al. Early detection of familial ovarian cancer. , 1996, European journal of cancer.
[81] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[82] M. Elwood. Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.
[83] E. Ferrazzi,et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[84] M. Grönroos,et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color doppler ultrasound , 1995, Cancer.
[85] A. Kurjak,et al. Three‐dimensional ultrasonographic and power Doppler characterization of ovarian lesions , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[86] Y. Saito,et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. , 2000, Cancer.
[87] I. Jacobs,et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation , 1999, British Journal of Cancer.
[88] B. Karlan,et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. , 1993, American journal of obstetrics and gynecology.
[89] J. X. Pang,et al. Biomarker discovery in urine by proteomics. , 2002, Journal of proteome research.
[90] Davor Jurkovic,et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network , 1999, British journal of obstetrics and gynaecology.
[91] M. Sakamoto,et al. Serum and tissue measurements of CA72-4 in ovarian cancer patients. , 1993, Gynecologic oncology.
[92] R. Bast,et al. Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer , 1992, Obstetrics and gynecology.
[93] B. Yin,et al. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK‐8): identification as a mucin‐type molecule , 1997, International journal of cancer.
[94] L. Valentin,et al. Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasound , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[95] C. Westhoff. Current status of screening for ovarian cancer. , 1994, Gynecologic oncology.
[96] M Markman,et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.
[97] M R Conaway,et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.
[98] S. Kupesic,et al. Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges , 1995, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[99] D. Fishman,et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. , 2001, Gynecologic oncology.
[100] M. Quinn,et al. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females , 1994, International Journal of Gynecologic Cancer.
[101] R. Kryscio,et al. Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter , 2003, Obstetrics and gynecology.
[102] John K. Gohagan,et al. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial , 2000 .
[103] T. Bourne,et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. , 1993, BMJ.
[104] G. Casey,et al. The familial ovarian cancer registry: progress report. , 1995, Cleveland Clinic journal of medicine.
[105] F. Kikkawa,et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125. , 1995, Gynecologic and obstetric investigation.
[106] T. Miyamoto,et al. Bilateral Oophorectomy in Asymptomatic Women over 50 Years Old Selected by Ovarian Cancer Screening , 1999, Gynecologic and Obstetric Investigation.
[107] L. Valentin,et al. Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.